631 related articles for article (PubMed ID: 25848209)
1. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
2. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
3. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
5. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
Ansell SM
Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
14. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
Pham A; Chen R
Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
17. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
19. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]